With UM being a rare melanoma, numbers of tumours are unnecessarily checked for BRAF mutational status, and many patients undergo 18F-Fluorodeoxyglucose PETCT and receive immunotherapy as for cutaneous melanoma. This evidence concerns the gene BRAF and cutaneous melanoma.